Journal article
Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer
Clinical advances in hematology & oncology, Vol.6(11), pp.825-833
11/2008
PMID: 19194367
Abstract
Tamoxifen has been used as adjuvant hormonal therapy for estrogen receptor positive breast cancer for over 30 years and is also widely used for the treatment of metastatic breast cancer. Tamoxifen is metabolized to its more active form by cytochrome P450 2D6 (CYP2D6); decreases in CYP2D6 activity, either by inactivating polymorphisms or drug interactions, can reduce concentrations of tamoxifen's active metabolites. Clinical studies demonstrate that breast cancer patients treated with adjuvant tamoxifen who have decreased CYP2D6 due to genetic polymorphisms or drug interactions may have an increased risk of recurrence and reductions in disease-free survival. Pharmacogenetic testing is currently available to predict CYP2D6 phenotypes and individualize tamoxifen therapy.
Details
- Title: Subtitle
- Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer
- Creators
- Cindy GastonJill Kolesar
- Resource Type
- Journal article
- Publication Details
- Clinical advances in hematology & oncology, Vol.6(11), pp.825-833
- PMID
- 19194367
- ISSN
- 1543-0790
- Language
- English
- Date published
- 11/2008
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696547802771
Metrics
2 Record Views